US FDA Requests Additional Data on Takeda’s Alogliptin
Takeda Pharmaceuticals have suffered a key setback after US regulators rejected their type 2 diabetes therapy, alogliptin, and the fixed-dose combination of the medicine with Takeda’s Actos. Actos lost patent protection in 2011, and generic versions of the drug are anticipated to hit the marketplace later this year. The business received a second complete response